Compare Stocks: QURE, EXEL, ARWR, and MDGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$87.47 -2.2%	$82.59	$19.82 ▼ $95.49	$12.59B	1.27	1.42 million shs	896,837 shs
EXEL Exelixis	$53.69 -1.3%	$54.24	$33.76 ▼ $57.57	$13.48B	0.44	2.73 million shs	1.95 million shs
MDGL Madrigal Pharmaceuticals	$519.09 -3.9%	$523.68	$392.96 ▼ $615.00	$12.48B	-1.01	385,853 shs	264,369 shs
QURE uniQure	$48.89 +0.3%	$42.98	$8.73 ▼ $71.50	$3.38B	0.92	1.40 million shs	1.20 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-2.17%	+2.20%	+17.38%	+16.70%	+333.02%
EXEL Exelixis	-1.29%	+6.09%	-4.33%	+7.06%	+41.81%
MDGL Madrigal Pharmaceuticals	-3.90%	+2.31%	-5.07%	+0.35%	+32.54%
QURE uniQure	+0.27%	+3.89%	+21.95%	+102.11%	+215.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$87.47 -2.2%	$82.59	$19.82 ▼ $95.49	$12.59B	1.27	1.42 million shs	896,837 shs
EXEL Exelixis	$53.69 -1.3%	$54.24	$33.76 ▼ $57.57	$13.48B	0.44	2.73 million shs	1.95 million shs
MDGL Madrigal Pharmaceuticals	$519.09 -3.9%	$523.68	$392.96 ▼ $615.00	$12.48B	-1.01	385,853 shs	264,369 shs
QURE uniQure	$48.89 +0.3%	$42.98	$8.73 ▼ $71.50	$3.38B	0.92	1.40 million shs	1.20 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-2.17%	+2.20%	+17.38%	+16.70%	+333.02%
EXEL Exelixis	-1.29%	+6.09%	-4.33%	+7.06%	+41.81%
MDGL Madrigal Pharmaceuticals	-3.90%	+2.31%	-5.07%	+0.35%	+32.54%
QURE uniQure	+0.27%	+3.89%	+21.95%	+102.11%	+215.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$97.33	11.28% Upside
EXEL Exelixis	2.30	Hold	$50.07	-6.75% Downside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$689.93	32.91% Upside
QURE uniQure	2.71	Moderate Buy	$65.00	32.95% Upside

Current Analyst Ratings Breakdown

Latest QURE, EXEL, ARWR, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform ➝ Hold
8/17/2026	ARWR Arrowhead Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/11/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B) ➝ Buy (A-)
8/6/2026	EXEL Exelixis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$56.00 ➝ $52.00
8/6/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$115.00 ➝ $120.00
8/6/2026	EXEL Exelixis	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$52.00
8/6/2026	EXEL Exelixis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$47.00 ➝ $51.00
8/4/2026	MDGL Madrigal Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$605.00
8/3/2026	MDGL Madrigal Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$964.00 ➝ $962.00
8/3/2026	EXEL Exelixis	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	14.85	$0.12 per share	748.83	$3.31 per share	26.43
EXEL Exelixis	$2.32B	5.73	$2.99 per share	17.97	$7.44 per share	7.22
MDGL Madrigal Pharmaceuticals	$958.40M	12.51	N/A	N/A	$22.67 per share	22.90
QURE uniQure	$16.10M	210.65	N/A	N/A	$4.67 per share	10.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	N/A
EXEL Exelixis	$782.57M	$3.18	16.88	14.43	1.62	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	93.53	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)

Latest QURE, EXEL, ARWR, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
EXEL Exelixis	N/A	3.46	3.38
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94
QURE uniQure	0.15	10.01	10.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
EXEL Exelixis	85.27%
MDGL Madrigal Pharmaceuticals	98.50%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
EXEL Exelixis	2.60%
MDGL Madrigal Pharmaceuticals	17.60%
QURE uniQure	4.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
MDGL Madrigal Pharmaceuticals	90	23.10 million	19.04 million	Optionable
QURE uniQure	500	69.37 million	66.14 million	Optionable

QURE, EXEL, ARWR, and MDGL Headlines

Recent News About These Companies

Royal Bank of Canada Increases Stock Position in uniQure N.V. $QURE

August 19 at 4:47 AM | marketbeat.com

uniQure Charts Accelerated Path With AMT‑130

August 16, 2026 | tipranks.com

Wall Street Zen Upgrades uniQure (NASDAQ:QURE) to "Hold"

August 15, 2026 | americanbankingnews.com

uniQure (NASDAQ:QURE) Upgraded by Wall Street Zen to "Hold" Rating

August 15, 2026 | marketbeat.com

Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE

August 10, 2026 | marketbeat.com

Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE

August 10, 2026 | marketbeat.com

uniQure (QURE) Q2 2026 Earnings Call Transcript

August 7, 2026 | finance.yahoo.com

uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Brokerages

August 7, 2026 | marketbeat.com

Militia Capital Management LLC Invests $1.54 Million in uniQure N.V. $QURE

August 3, 2026 | marketbeat.com

Equities Analysts Issue Forecasts for uniQure Q3 Earnings

August 3, 2026 | marketbeat.com

uniQure (NASDAQ:QURE) Stock Rating Lowered by Wall Street Zen

August 1, 2026 | marketbeat.com

uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course

July 31, 2026 | seekingalpha.com

Barclays Keeps Their Buy Rating on uniQure (QURE)

July 31, 2026 | theglobeandmail.com

UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma

July 31, 2026 | biospace.comB

QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

July 30, 2026 | zacks.com

Wells Fargo & Company Issues Positive Forecast for uniQure (NASDAQ:QURE) Stock Price

July 30, 2026 | marketbeat.com

uniQure N.V. (QURE) Q2 2026 Earnings

July 30, 2026 | 247wallst.com

UniQure outlines AMT-130 BLA this quarter, supported by cash runway into 2030

July 30, 2026 | seekingalpha.com

AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says

July 30, 2026 | finance.yahoo.com

Stempoint Capital LP Has $1.28 Million Stock Position in uniQure N.V. $QURE

July 30, 2026 | marketbeat.com

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

July 29, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, EXEL, ARWR, and MDGL Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$87.47 -1.94 (-2.17%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$86.40 -1.07 (-1.23%)

As of 08/20/2026 05:39 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Exelixis NASDAQ:EXEL

$53.69 -0.70 (-1.29%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$53.86 +0.17 (+0.32%)

As of 08/20/2026 06:01 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$519.09 -21.07 (-3.90%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$521.50 +2.41 (+0.47%)

As of 08/20/2026 06:32 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

uniQure NASDAQ:QURE

$48.89 +0.13 (+0.27%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$49.25 +0.36 (+0.74%)

As of 08/20/2026 06:18 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QURE, EXEL, ARWR, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QURE, EXEL, ARWR, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QURE, EXEL, ARWR, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, EXEL, ARWR, and MDGL Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Exelixis NASDAQ:EXEL

Madrigal Pharmaceuticals NASDAQ:MDGL

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QURE, EXEL, ARWR, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QURE, EXEL, ARWR, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QURE, EXEL, ARWR, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, EXEL, ARWR, and MDGL Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Exelixis NASDAQ:EXEL

Madrigal Pharmaceuticals NASDAQ:MDGL

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools